Publications by authors named "Robert Croop"

Claim this Profile
E
Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double-blind, randomized controlled trial.
Koichi Ikeda, Yasuhiko Matsumori, Masako Kudo, Tomofumi Ishikawa, Yuko Hoshino, Robert Croop

Headache· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain Language Summary Publication: Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
Shigekazu Kitamura, Yasuhiko Matsumori, Toshimasa Yamamoto, Tomofumi Ishikawa, Yuko Hoshino, Robert Croop

Headache· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals.
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T Matschke, Richard Bertz, Robert Croop

Clin Pharmacol Drug Dev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine.
Chay Ngee Lim, Gary Mo, Rajinder Bhardwaj, Craig M Comisar, Beth L Emerson, Robert Croop

Headache· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
Shigekazu Kitamura, Yasuhiko Matsumori, Toshimasa Yamamoto, Tomofumi Ishikawa, Yuko Hoshino, Robert Croop

Headache· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral rimegepant as a preventive treatment of migraine: a plain language summary of a clinical study.
Robert Croop, Richard B Lipton, David Kudrow, Lisa Kamen, Charles M Conway

Pain Manag· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo-controlled trials.
Richard Bertz, Mary Donohue, Jennifer Madonia, Rajinder Bhardwaj, Kyle T Matschke, Robert Croop

Headache· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open-label, single-dose, parallel-group study.
Rajinder Bhardwaj, Beth Morris, Richard Bertz, Kyle Matschke, Robert Croop

Headache· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rimegepant orally disintegrating tablet for acute treatment of migraine: a plain language summary of a clinical study.
Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw

Pain Manag· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine.
David Kudrow, Robert S Croop, Alexandra Thiry, Richard B Lipton

Headache· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam.
Rajinder Bhardwaj, Beth Morris, Kyle T Matschke, Richard Bertz, Robert Croop

Headache· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo-controlled study in healthy adults.
Rajinder Bhardwaj, Mary K Donohue, Jennifer Madonia, Kyle Matschke, Matt S Anderson, Robert Croop

Headache· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deconvoluting zavegepant drug-drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics.
Rajinder Bhardwaj, Jo Ann Malatesta, Jennifer Madonia, Matt S Anderson, Beth Morris, Robert Croop

Clin Transl Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study.
David True, Kathleen Mullin, Robert Croop

Pain Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects.
Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, Matt S Anderson, Kyle Matschke, Robert Croop

Clin Transl Sci· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study.
Kathleen Mullin, Robert Croop, Linda Mosher, Terence Fullerton, Jennifer Madonia

Cephalalgia· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.
Rajinder Bhardwaj, Mary K Donohue, Jennifer Madonia, Beth Morris, Thomas C Marbury, Robert Croop

Clin Transl Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.
Richard B Lipton, Alexandra Thiry, Beth A Morris, Robert Croop

J Pain Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval.
Jim H Hughes, Richard Bertz, Rajinder Bhardwaj, Mary K Donohue, Jennifer Madonia, Robert S Croop

CPT Pharmacometrics Syst Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
Rajinder Bhardwaj, Beth Morris, Kyle Matschke, Richard Bertz, Robert Croop

Clin Pharmacol Drug Dev· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States.
Gary Berman, Alexandra Thiry, Robert Croop

J Pain Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Robert Croop

J Headache Pain· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry

Cephalalgia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults.
Rajinder Bhardwaj, Michael S Hanna, Beth A Morris, Kyle T Matschke, Richard Bertz, Robert S Croop

Clin Transl Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults.
Robert Croop, Rajinder Bhardwaj, Matt S Anderson, Kyle T Matschke, Jennifer Hould

Cephalalgia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis